Amphotericin B: A drug of choice for Visceral Leishmaniasis

Kumari, Shipra; Kumar, Vikash; Tiwari, Ritesh Kumar; Ravidas, Vidyanand; Pandey, Krishna; Kumar, Ashish

doi:10.1016/j.actatropica.2022.106661

Cited by 39 publications

(29 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Leishmania donovani is a protozoan parasite that causes persistent visceral leishmaniasis, known also as Kala azar, transmitted via the bite of phlebotome sand flies as the preferred vector [ 55 ]. The Leishmania donovani life cycle entails a promomastigote found in the vector and amastigote found in the host.…”

Section: Antimicrobial Productsmentioning

confidence: 99%

See 1 more Smart Citation

Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus

et al. 2023

View full text Add to dashboard Cite

Lactoferrin is an 80 kDa monomeric glycoprotein that exhibits multitask activities. Lactoferrin properties are of interest in the pharmaceutical field for the design of products with therapeutic potential, including nanoparticles and liposomes, among many others. In antimicrobial preparations, lactoferrin has been included either as a main bioactive component or as an enhancer of the activity and potency of first-line antibiotics. In some proposals based on nanoparticles, lactoferrin has been included in delivery systems to transport and protect drugs from enzymatic degradation in the intestine, favoring the bioavailability for the treatment of inflammatory bowel disease and colon cancer. Moreover, nanoparticles loaded with lactoferrin have been formulated as delivery systems to transport drugs for neurodegenerative diseases, which cannot cross the blood–brain barrier to enter the central nervous system. This manuscript is focused on pharmaceutical products either containing lactoferrin as the bioactive component or formulated with lactoferrin as the carrier considering its interaction with receptors expressed in tissues as targets of drugs delivered via parenteral or mucosal administration. We hope that this manuscript provides insights about the therapeutic possibilities of pharmaceutical Lf preparations with a sustainable approach that contributes to decreasing the resistance of antimicrobials and enhancing the bioavailability of first-line drugs for intestinal chronic inflammation and neurodegenerative diseases.

show abstract

Section: Antimicrobial Productsmentioning

confidence: 99%

“…The Leishmania donovani life cycle entails a promomastigote found in the vector and amastigote found in the host. Amphotericin B, the first choice for antiprotozoan treatment, is highly toxic and eventually loses efficiency because of the development of protozoan resistance [ 55 ].…”

Section: Antimicrobial Productsmentioning

confidence: 99%

Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Regarding combined antifungal therapy, results obtained so far are also promising. The combination of parenterally administered amphotericin B (AmB) with azoles (i.e., posaconazole, itraconazole, fluconazole) is especially useful in critically ill patients for whom the administration of high doses of AmB is contraindicated due to the high risk of adverse effects, including renal failure, dyspnoea, hypokalaemia, nausea, vomiting and infusion-related chills when using Fungizone® [12,13]. Although the risk of nephrotoxicity has been diminished since liposomal AmB (AmBisome®) has been implemented in clinic, patients might still experience with the other adverse effects such as anemia [14,15].…”

Section: Introductionmentioning

confidence: 99%

Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses

Fernández-García

Walsh

O’Connell

et al. 2023

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

“…Unfortunately, the widespread use of AmBisome ® and its generics remains limited by their low stability at temperatures higher than 25 °C and the need for parenteral administration [ 14 , 18 , 19 ]. Furthermore, AmBisome ® showed moderate efficacies in New World CL, with a cure rate lower than 80% [ 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

et al. 2022

View full text Add to dashboard Cite

The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB.

show abstract

Amphotericin B: A drug of choice for Visceral Leishmaniasis

Cited by 39 publications

References 170 publications

Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus

Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus

Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

Contact Info

Product

Resources

About